This is a standard pre-commercial CMO agreement — no new cash outlays or revenue implications disclosed. The real catalysts remain veligrotug's FDA approval path and upcoming clinical data. Monitor the 10-Q filing for the full agreement text to assess any hidden minimum purchase obligations or termination penalties.
Price Chart
Executive Summary
Viridian Therapeutics entered into a commercial manufacturing services agreement with WuXi Biologics for long-term supply of veligrotug (VRDN's lead asset) drug substance and product, contingent on regulatory approval. The non-exclusive, five-year renewable deal secures volume-based pricing with fixed rates through year-end 2026, but WuXi remains an alternate supplier and VRDN can use other manufacturers. This is a routine operational step for a pre-commercial biotech — the filing confirms no financial terms or minimum commitments were disclosed.
Key Facts
- Commercial manufacturing services agreement signed May 24, 2026 with WuXi Biologics
- Covers veligrotug drug substance and drug product for commercial use, if approved
- Non-exclusive supply; Viridian may use alternate manufacturers
- Volume-based pricing; service fee fixed through December 31, 2026
- Initial 5-year term with automatic 5-year renewals unless 24-month non-renewal notice
- No financial terms (upfront, minimum purchase, or volume commitments) disclosed in the filing
- Viridian intends to file the full agreement as an exhibit to its June 30, 2026 10-Q
Financial Impact
No financial terms disclosed — deal has no stated upfront payment, minimum commitment, or revenue impact. Only pass-through costs and volume-based pricing described.
Risk Factors
- WuXi Biologics is a Hong Kong-based manufacturer; geopolitical or regulatory changes could disrupt supply
- No binding volume minimums disclosed — VRDN's commercial launch depends on FDA approval, which is uncertain
- Agreement allows VRDN to use alternate manufacturers, limiting WuXi's leverage but also potential supply constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-239246 |
| Document: 0001193125-26-239246-index-headers.html | 0001193125-26-239246 |
| Document: 0001193125-26-239246-index.html | 0001193125-26-239246 |
| Document: 0001193125-26-239246.txt | 0001193125-26-239246 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $22.51 $22.96 | ▲ +2.00% | ▲ +1.40% | $23.34 (+3.69%) |
May 28, 2026 21w ago | 8-K | $17.62 $18.79 | ▲ +6.64% | ▲ +8.43% | $23.34 (+32.46%) |
May 26, 2026 21w ago | 8-K | $17.26 $17.39 | ▲ +0.75% | ▲ +2.65% | $23.34 (+35.23%) |
May 8, 2026 24w ago | 424B5 | $17.20 $16.31 | ▲ +5.17% | ▲ +4.87% | $23.34 (−35.70%) |
May 5, 2026 24w ago | 424B5 | $17.53 $16.35 | ▼ −6.73% | ▼ −9.51% | $23.34 (+33.14%) |
May 5, 2026 24w ago | 8-K | $18.75 $15.87 | ▼ −15.36% | ▼ −20.31% | $23.34 (+24.48%) |
Apr 17, 2026 27w ago | DEFA14A | $14.80 $17.43 | ▲ +17.77% | ▲ +12.40% | $23.34 (+57.70%) |
Feb 26, 2026 34w ago | 8-K | $29.49 $28.20 | ▼ −4.37% | ▲ +2.03% | $23.34 (−20.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers